13 May 2025 in Rheumatology
Objectives: Recent guidelines and recommendations for LN suggest rapid glucocorticoid (GC) reduction; however, robust supporting evidence remains limited. This study aimed to evaluate the impact of rapid GC reduction on renal outcomes in patients with proliferative LN. Methods: We conducted a multicentre retrospective chart review of patients with GC-naïve, biopsy-proven proliferative LN with available urinary protein-to-creatinine ratio (UPCR) data before and 52 weeks after GC treatment. Patients who reduced their prednisolone-equivalent dose to ≤7.5 mg/day within 6 months (rapid GC reducers) were compared with those who did not (conventional GC reducers) regarding partial renal response (PRR) at 12 months. Modified Poisson regression analysis was used to adjust for confounding factors. Results: A total of 344 patients from 17 centres were included: 50 rapid GC reducers and 294 conventional GC reducers. PRR at 12 months was achieved by 43/50 (86%) in the rapid GC group and 248/294 (84.4%) in the conventional group. After adjusting for age, initial UPCR, initial estimated glomerular filtration rate, the presence of a concomitant membranous lesion in the glomerulus, initial GC dose, use of methylprednisolone pulse therapy, strong immunosuppressants (mycophenolate mofetil, cyclophosphamide or rituximab) and hydroxychloroquine, no significant difference was observed in PRR at 12 months (adjusted risk ratio: 0.92, P = 0.758). Relapse rates and serious adverse events over 2 years of follow-up were also comparable between the groups. Conclusion: Rapid GC reduction to ≤7.5 mg/day within 6 months did not compromise renal outcomes or increase relapse in proliferative LN.
25 June 2025 in Rheumatology
Objectives: The treat-to-target (T2T) approach for SLE has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS) and SLE-DAS LDA. Methods: A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D. Results: This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria. Conclusion: Remission and LDA criteria based on the safety of oestrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.
15 March 2025 in Modern Rheumatology
Objective: : Recent systemic lupus erythematosus (SLE) guidelines recommend using hydroxychloroquine (HCQ) at <5.0 mg/kg/day to reduce retinopathy risk but note that doses below this may increase flare risk, suggesting 5.0 mg/kg/day as ideal. Evidence is insufficient, especially among the Japanese. Method: : We retrospectively analysed 321 SLE patients treated with HCQ at Juntendo University Hospital between December 2015 and March 2019. They were divided into a low-dose group (<5 mg/kg/day, n = 205) and a high-dose group (≥5 mg/kg/day, n = 116). This study compared side effect discontinuation rates, flare rates, and treatment efficacy in Japanese SLE patients according to HCQ dosage, evaluating changes in Systemic Lupus Erythematosus Disease Activity Index, glucocorticoid dosage, complement activity, and anti-ds DNA antibody titer. Results: : Three hundred and twenty-one patients were followed for a median of 66 months. The side effect discontinuation rate was not significantly different. SLE flare rates were 5.4% in the low-dose group and 8.6% in the high-dose group, with no significant difference (P = .170). While the high-dose group showed a trend towards better treatment efficacy for secondary outcomes, the differences were not statistically significant. Conclusion: : There was no significant difference in flare incidence based on HCQ dosage. In the maintenance phase of remission, a lower dosage may be sufficient.
24 November 2025 in Lupus
Objectives: In systemic lupus erythematosus (SLE), a serologically active clinically quiescent (SACQ) state is defined as one in which high anti-DNA antibody levels or low complement levels persist, however, disease activity remains stable. Although treatment intensification is not recommended for the SACQ state under the Treat to Target strategy, SACQ has been reported to be a risk factor for flares. The present study aimed to evaluate the efficacy of adding belimumab (BLM) to hydroxychloroquine (HCQ), the standard treatment for SLE, for patients in the SACQ state. Methods: Patients treated with BLM were defined as the exposure group and those who did not were defined as the control group. Propensity score analysis with inverse probability of treatment weighting was used to analyze outcomes. The primary outcome was analyzed using the Kaplan–Meier method to determine time-to-event achievement to reduce prednisolone (PSL) dose to 7.5 mg/day or 5 mg/day. Secondary outcomes were as follows: (1) time to flares, analyzed using the Kaplan–Meier method, and (2) difference in median PSL dose at the last observation, analyzed using the Mann–Whitney U-test. Results: Of the 146 patients in the SACQ state who received HCQ, 27 were included in the exposure group and 107 in the control group. The primary outcome, time-to-event achievement to reduce PSL dose to 7.5 mg/day and 5 mg/day had an HR value of 1.21 (95% confidence interval (CI) 0.78–1.89, p = 0.396) and 1.19 (95% CI 0.74–1.89, p = 0.471) in the two groups, respectively, with no significant difference between the two groups. No significant differences were observed in other outcomes. Conclusions: Adding BLM to HCQ in patients in the SACQ state did not demonstrate effects in preventing flares or reducing glucocorticoids (GC) dose.
1 July 2026 in Lupus Science & Medicine